MRTX849 - Adagrasib

Based on 84 reference(s) in Google Scholar 8 10 84

Axon 4036

CAS [2326521-71-3]

MF C32H35ClFN7O2
MW 604.12

  • Purity: 99%
  • Optical purity: 99% d.e.
  • Soluble in DMSO

MRTX849

Description

MRTX849 is an orally available, potent, mutation-selective, and irreversible covalent inhibitor of KRAS-G12C, currently under evaluation as antitumor therapies by modulating KRAS-dependent signal transduction as a single agent, or in combination of with SHP2 inhibitor TNO155.

KEYWORDS: MRTX849 | Supplier | KRAS-G12C inhibitor | Adagrasib | MRTX-849 | MRTX 849 | CT-MRTX849 | CAS [2326521-71-3] | GTP | KRAS | Inhibitor | Enzymes

Potent, mutation-selective, and irreversible covalent inhibitor of KRAS-G12C

Chemical name

2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

Source information

Sold in collaboration with Chemietek

Parent CAS No.

[2326521-71-3]

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...